NRIX
Nurix Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.61B
P/E Ratio
—
EPS
$-2.92
Beta
1.98
52W High
$22.50
52W Low
$8.20
50-Day MA
$15.96
200-Day MA
$13.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | $71.78M |
| Gross Profit (TTM) | $-259.60M |
| EBITDA | $-307.31M |
| Operating Margin | -1479.00% |
| Return on Equity | -61.40% |
| Return on Assets | -31.50% |
| Revenue/Share (TTM) | $0.77 |
| Book Value | $5.29 |
| Price-to-Book | 2.98 |
| Price-to-Sales (TTM) | 22.47 |
| EV/Revenue | 12.71 |
| EV/EBITDA | -3.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -66.10% |
| Shares Outstanding | $103.41M |
| Float | $87.14M |
| % Insiders | 1.10% |
| % Institutions | 110.95% |
Analyst Ratings
Consensus ($30.00 target)
5
Strong Buy12
BuyData last updated: 4/9/2026